Navigation Links
Proof of Concept Study Initial Findings
Date:1/28/2013

PERTH, Australia, Jan. 28, 2013 /PRNewswire/ -- Bone Medical Ltd (ASX: BNE), a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

These first results confirm that BN006 reduces inflammation in a collagen-antibody induced arthritis disease model, a widely used benchmark for evaluating and comparing novel treatments for RA. The reduction appeared to be dose-related.

Significantly, BN006 achieved notable reduction in inflammation with only a modest reduction of TNF. TNF is one of the body's inflammatory agents that play an important role in the RA disease process.  BN006 has also been shown to reduce IL-6, another cytokine involved in RA.

Dr Roger New , CSO and inventor of the Mozaic™ system, explained, "The current standard of care for the treatment of RA works by binding to TNF and blocking its activity systemically.  This approach reduces TNF's ability to play its role in the body's immune response, leading to the adverse events that most commonly limit the clinical role of these products."

"In our study, BN006 achieved its effect with only a small reduction in TNF," continued Dr New. "While adalimumab (Humira™) eliminated inflammation in our study, it almost completely blocked TNF.  This provides experimental evidence for BN006's selective mechanism of action, which acts directly on macrophages to reduce their inflammatory activity, and confirms its potential to become an important advance in the treatment for RA."

Dr New said the Company was continuing to evaluate the results of the study, and would add another BN006 treatment arm to further expand the study outcomes.  More complete results are expected over the next couple of months.Contact:Dr Roger NewPeter YoungChairmanCEO+44 207 794 1512

+1 201 841 9681Leon IvoryDirector+61 419 428 264

or visit: www.bone-ltd.comAbout Bone Medical LimitedBone Medical Limited focuses on developing significant new products for the treatment of bone diseases like osteoarthritis, rheumatoid arthritis, and osteoporosis.  The Company's product pipeline includes Phase II clinical-stage programs for the oral delivery of CaPTHymone™ (parathyroid hormone) for osteoporosis and Capsitonin™ (calcitonin) for osteoarthritis pain and osteoporosis, and novel preclinical-stage compounds like BN006, BN007, a collagen tolerance & joint protection agent for RA, and BN005 & BN008, bone cell regulators for osteoporosis.

 


'/>"/>
SOURCE Bone Medical Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
2. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
3. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
4. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
5. A New Audio Interview With Ronald Adams President Of Medical Alarm Concepts Holding, Inc., Is Now At SmallCapVoice.com
6. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
7. Medical Alarm Concepts Publishers Shareholder Letter
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
10. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
11. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... ) pursuant and/or traceable to Kitov,s initial public offering ... on the open market from November 20, 2015 through ... The lawsuit seeks to recover damages for Kitov investors ...
(Date:3/28/2017)... , March 29, 2017 ... Siteless CRO platform, announced today study results ... Managed Care Pharmacy, #AMCP2017, Managed Care and Specialty Pharmacy ... . Data in both posters demonstrated that pharmacist-led ... and protocol adherence. These factors are crucial to generating ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is the first technology to directly address the resolution to globally reduce the ... is a patented compound of FDA and TTB approved ingredients that when infused ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
Breaking Medicine News(10 mins):